Company

VytronUS, Inc. was formed in 2006 to harness the imaging and therapeutic capabilities of ultrasound energy to treat cardiac arrhythmias, starting with atrial fibrillation. We recognize that today's marketed technologies have limitations. Only a new energy source, such as collimated ultrasound, can shift the treatment paradigm to more predictable outcomes. We strive to make a complicated procedure simple. Ease of use guides every aspect of our design philosophy. At VytronUS, patient safety is always our first priority and improved efficacy is our mission. We look forward to making our products available to doctors and their patients in the near future.